Sign In
Buy BBI
$1.94
+0 (+0%)
At Close: Feb 07, 2023
Brickell (BBI) Reports Q2 Loss, Tops Revenue Estimates
07:19pm, Thursday, 12'th Aug 2021
Brickell (BBI) delivered earnings and revenue surprises of -45.45% and 51.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2021 Results - Earnings Call Transcript
06:51pm, Thursday, 12'th Aug 2021
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2021 Results - Earnings Call Transcript
Brickell (BBI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:44pm, Thursday, 05'th Aug 2021
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
08:00am, Thursday, 29'th Jul 2021
BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated pre
Why Brickell Biotech Shares Are Trading Lower Today
03:37pm, Tuesday, 20'th Jul 2021
Brickell Biotech (NASDAQ: BBI) shares are trading lower after the company announced a bought deal offering of common stock of $5 million, which was later increased to $7 million. Brickell Biotech is a
BBI Stock Fell Over 20% Pre-Market: Why It Happened
07:33am, Tuesday, 20'th Jul 2021
The stock price of Brickell Biotech Inc (NASDAQ: BBI) fell by over 20% pre-market. This is why it happened.
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
10:44pm, Monday, 19'th Jul 2021
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
05:25pm, Monday, 19'th Jul 2021
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative a
Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021 Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript
07:55pm, Thursday, 13'th May 2021
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates
06:56pm, Thursday, 13'th May 2021
Brickell (BBI) delivered earnings and revenue surprises of -25.00% and -83.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech: Q1 Earnings Insights
04:30pm, Thursday, 13'th May 2021
Shares of Brickell Biotech (NASDAQ:BBI) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.15), which
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
03:46pm, Thursday, 06'th May 2021
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
08:00am, Thursday, 29'th Apr 2021
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated pr
Phase 3 Pivotal Cardigan II study exceeds 50% enrollment - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021
